Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

See allHide authors and affiliations

Science  11 Jun 2021:
Vol. 372, Issue 6547, pp. 1224-1229
DOI: 10.1126/science.abe9985

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • RE: Prediabetes

    Letter to the Editors

    Interesting work on clinical studies boosting NAD+ (Science June 11, 2021) is described by Yoshino et al (p. 1224) and summarized by Hepler et al (p. 1147). The studies were carried out on postmenopausal prediabetic women. The authors suggest that their findings might lead to a health supplement to prevent prediabetes.

    However, Science published a compelling report on the dubious existence of such a condition as prediabetes (Piller, Mar 7, 2019). The article also cited efforts by the American Diabetes Association to promote the acceptance of this condition even though supporting data was weak at best.

    It is unfortunate that neither Hepler or Yoshino acknowledged the controversial nature of the prediabetes diagnosis. I think the Science editors should have stepped in and required a comment on this.

    Blaise J. Arena
    AAAS member

    Competing Interests: None declared.

Stay Connected to Science